Radiodermatitis-Pipeline Review, H1 2015

Radiodermatitis-Pipeline Review, H1 2015

  • Products Id :- GMDHC6799IDB
  • |
  • Pages: 45
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Radiodermatitis-Pipeline Review, H1 2015


Global Markets Direct's, 'Radiodermatitis-Pipeline Review, H1 2015', provides an overview of the Radiodermatitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Radiodermatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Radiodermatitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Radiodermatitis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Radiodermatitis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Radiodermatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Radiodermatitis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Radiodermatitis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Radiodermatitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Radiodermatitis Overview 6

Therapeutics Development 7

Pipeline Products for Radiodermatitis-Overview 7

Pipeline Products for Radiodermatitis-Comparative Analysis 8

Radiodermatitis-Therapeutics under Development by Companies 9

Radiodermatitis-Pipeline Products Glance 10

Clinical Stage Products 10

Early Stage Products 11

Radiodermatitis-Products under Development by Companies 12

Radiodermatitis-Companies Involved in Therapeutics Development 13

APEIRON Biologics AG 13

ProCertus BioPharm Inc. 14

Reata Pharmaceuticals, Inc. 15

Stemnion, Inc 16

Vida Therapeutics Inc. 17

Radiodermatitis-Therapeutics Assessment 18

Assessment by Monotherapy Products 18

Assessment by Target 19

Assessment by Mechanism of Action 21

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Drug Profiles 27

Amnion Derived Cellular Cytokine Solution-Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

APN-201-Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

PrC-210-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

RTA-408-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

VTI-1000 Series-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Radiodermatitis-Recent Pipeline Updates 36

Radiodermatitis-Dormant Projects 38

Radiodermatitis-Discontinued Products 39

Radiodermatitis-Product Development Milestones 40

Featured News & Press Releases 40

Jul 25, 2014: Reata Enrolls First Patient in the PRIMROSE Study, a Phase 2 Study Examining RTA 408 in Breast Cancer Patients at Risk for Radiation Dermatitis 40

Apr 24, 2014: RTA 408 Lotion Demonstrates Favorable Safety and Pharmacodynamic Response in a Phase 1 Study 40

Apr 10, 2014: Preclinical Study of Reata's RTA 408 Demonstrates Role in Prevention and Treatment of Radiation Dermatitis 41

Mar 05, 2013: Apeiron Biologics's Liposomal Formulation Of Recombinant Superoxide Dismutase Achieves All Endpoints In Clinical Study 41

Aug 22, 2012: Apeiron Biologics Receives 510,000 ZIT Grant For Further Development Of APN201 Project 42

Feb 27, 2012: Apeiron Initiates Clinical Study To Investigate Prevention Of Radiation-Induced Skin Damage In Breast Cancer Patients 42

Appendix 44

Methodology 44

Coverage 44

Secondary Research 44

Primary Research 44

Expert Panel Validation 44

Contact Us 44

Disclaimer 45

List of Tables

Number of Products under Development for Radiodermatitis, H1 2015 7

Number of Products under Development for Radiodermatitis-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Clinical Stage Development, H1 2015 10

Comparative Analysis by Early Stage Development, H1 2015 11

Products under Development by Companies, H1 2015 12

Radiodermatitis-Pipeline by APEIRON Biologics AG, H1 2015 13

Radiodermatitis-Pipeline by ProCertus BioPharm Inc., H1 2015 14

Radiodermatitis-Pipeline by Reata Pharmaceuticals, Inc., H1 2015 15

Radiodermatitis-Pipeline by Stemnion, Inc, H1 2015 16

Radiodermatitis-Pipeline by Vida Therapeutics Inc., H1 2015 17

Assessment by Monotherapy Products, H1 2015 18

Number of Products by Stage and Target, H1 2015 20

Number of Products by Stage and Mechanism of Action, H1 2015 22

Number of Products by Stage and Route of Administration, H1 2015 24

Number of Products by Stage and Molecule Type, H1 2015 26

Radiodermatitis Therapeutics-Recent Pipeline Updates, H1 2015 36

Radiodermatitis-Dormant Projects, H1 2015 38

Radiodermatitis-Discontinued Products, H1 2015 39

List of Figures

Number of Products under Development for Radiodermatitis, H1 2015 7

Number of Products under Development for Radiodermatitis-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Clinical Stage Development, H1 2015 10

Assessment by Monotherapy Products, H1 2015 18

Number of Products by Top 10 Targets, H1 2015 19

Number of Products by Stage and Top 10 Targets, H1 2015 19

Number of Products by Top 10 Mechanism of Actions, H1 2015 21

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 21

Number of Products by Top 10 Routes of Administration, H1 2015 23

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 23

Number of Products by Top 10 Molecule Types, H1 2015 25

Number of Products by Stage and Top 10 Molecule Types, H1 2015 25

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@]

APEIRON Biologics AG

ProCertus BioPharm Inc.

Reata Pharmaceuticals, Inc.

Stemnion, Inc

Vida Therapeutics Inc.

Radiodermatitis Therapeutic Products under Development, Key Players in Radiodermatitis Therapeutics, Radiodermatitis Pipeline Overview, Radiodermatitis Pipeline, Radiodermatitis Pipeline Assessment

select a license

Single User License
USD 2000 INR 127880
Site License
USD 4000 INR 255760
Corporate User License
USD 6000 INR 383640



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

query [@]